Applied DNA Sciences, Inc. (NASDAQ:APDN) Short Interest Up 40.4% in January

Applied DNA Sciences, Inc. (NASDAQ:APDN) was the recipient of a large increase in short interest in the month of January. As of January 15th, there was short interest totalling 7,060,000 shares, an increase of 40.4% from the December 31st total of 5,030,000 shares. Based on an average trading volume of 5,960,000 shares, the days-to-cover ratio is currently 1.2 days.

Institutional Investors Weigh In On Applied DNA Sciences

A hedge fund recently bought a new stake in Applied DNA Sciences stock. Jane Street Group LLC acquired a new stake in Applied DNA Sciences, Inc. (NASDAQ:APDN) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 73,396 shares of the technology company’s stock, valued at approximately $48,000. Jane Street Group LLC owned 0.24% of Applied DNA Sciences as of its most recent SEC filing. 22.22% of the stock is currently owned by hedge funds and other institutional investors.

Applied DNA Sciences Trading Down 1.6 %

APDN stock traded down $0.00 during mid-day trading on Friday, hitting $0.18. 888,198 shares of the company were exchanged, compared to its average volume of 3,507,903. Applied DNA Sciences has a 1-year low of $0.12 and a 1-year high of $14.40. The stock has a market capitalization of $9.66 million, a PE ratio of -0.03 and a beta of 0.40. The business has a 50 day simple moving average of $0.19 and a 200-day simple moving average of $0.54.

Applied DNA Sciences (NASDAQ:APDN) last released its quarterly earnings results on Tuesday, December 17th. The technology company reported ($0.32) earnings per share for the quarter, topping the consensus estimate of ($0.33) by $0.01. Applied DNA Sciences had a negative return on equity of 111.18% and a negative net margin of 203.76%. Equities research analysts expect that Applied DNA Sciences will post -0.87 earnings per share for the current year.

About Applied DNA Sciences

Applied DNA Sciences, Inc, a biotechnology company, develops and commercializes technologies to produce and detect deoxyribonucleic acid (DNA) in the Americas, Europe, Asia, and internationally. It operates through three segments: Therapeutic DNA Production Services; MDx Testing Services; and DNA Tagging and Security Products and Services.